series-b
Stage
2013
Founded
1
Investors
About
TILT Biotherapeutics is a clinical-stage biotechnology company developing next-generation oncolytic viral immunotherapies for solid tumors. Their lead investigational therapy, TILT-123 (igrelimogene litadenorepvec), is an intravenously delivered adenoviral therapy armed with TNF and IL-2 intended to stimulate anti-tumor T-cell responses.
Explore TILT Biotherapeutics Oy's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.